Recuperación exitosa de fondos en nombre de inversionistas en una empresa farmacéutica con sede en China
Robert Seiden, appointed receiver over Shengtai Pharmaceutical, structured a buyout of U.S. investors' shares at $1.65/share, even though the stock was trading at $0.12/share, for an approximate $4 million court-approved settlement.
On April 3, 2014, Robert Seiden was appointed Receiver over Shengtai Pharmaceutical, Inc., a U.S. publicly-listed company with Hong Kong and China operations. Seiden was able to structure a deal with the company chairman that bought out shares of U.S. investors at $1.65 per share, even though the stock was trading at $0.12 per share.
The settlement was approved by the court and all parties; shareholders received their funds, totaling approximately $4 million. The case has been widely covered in the media by reputable sources, including the Wall Street Journal and the New York Times.
English 
Russian 
Chinese 
Spanish 
Hebrew 
Arabic